New drug ADCE-B05 targets Hard-to-Treat cancers in first human trial

NCT ID NCT07362888

First seen Jan 27, 2026 · Last updated May 14, 2026 · Updated 21 times

Summary

This early-phase study tests a new drug called ADCE-B05 in people with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and to check for side effects. About 180 adults will take part, and the drug is given alone at different dose levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS (PHASE 1) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Highlands Oncology Group

    RECRUITING

    Springdale, Arkansas, 72762, United States

  • Monash Health

    NOT_YET_RECRUITING

    Clayton, South Australia, 3165, Australia

  • Peter MacCallum Cancer Centre

    NOT_YET_RECRUITING

    Melbourne, Victoria, 3000, Australia

  • Scientia Clinical Research

    RECRUITING

    Randwick, New South Wales, 2031, Australia

  • Southern Oncology Clinical Research Unit

    RECRUITING

    Bedford Park, South Australia, 5042, Australia

  • University Of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

  • Yale University

    NOT_YET_RECRUITING

    New Haven, Connecticut, 06520, United States

Conditions

Explore the condition pages connected to this study.